In the unpredictable theater of global finance, few figures command attention quite like Donald J. Trump. His pronouncements, often delivered with the subtlety of a sledgehammer, consistently send ripples, if not tidal waves, through the stock markets. The closing weeks of 2025 have proven no exception, offering a fresh batch of market-moving maneuvers that leave analysts scratching their heads and investors reaching for their antacids. From “historic” drug price cuts that somehow boost pharma stocks to a social media platform merging with a nuclear fusion company, and the ever-present specter of tariffs, the market’s relationship with Trump remains a captivating, if chaotic, spectacle.
The Art of the Deal, Pharma Edition: When Price Cuts Mean Profits
On Friday, December 19, 2025, President Trump unveiled what his administration hailed as “the biggest thing having to do with drugs in the history of the purchase of drugs”. This grand declaration accompanied the announcement of deals with nine major pharmaceutical companies – including industry titans like Amgen, Bristol Myers Squibb, Gilead Sciences, GSK, Merck & Co., Novartis, Roche’s Genentech, and Sanofi – aimed at significantly lowering drug prices for Medicaid beneficiaries and cash-paying patients. These agreements, part of the “Most Favored Nation” initiative, ostensibly seek to align U.S. drug costs with the more modest prices found in other developed nations.
One might expect such news to send shivers down the spines of pharmaceutical investors. After all, “price cuts” usually don’t rhyme with “profit surges.” Yet, in a testament to the peculiar logic of the Trump market, shares of most of the involved drugmakers actually rose. On December 19, GSK, Merck, Amgen, Novartis, Sanofi, and Roche all saw their stock prices climb by approximately 1% to 3%. The rationale? These deals, for all their headline-grabbing fanfare, effectively removed the immediate threat of more punitive tariffs on pharmaceutical products for the next three years. Investors, it seems, are more concerned with avoiding the stick than with the potential impact of a carrot dangled for consumers.
Analysts, ever the purveyors of sober reality, were quick to offer their unvarnished takes. Bernstein analyst Courtney Breen observed, with a hint of weary resignation, that “These deals re-affirm that the pharma leaders have taken this opportunity to collaborate with this administration to deliver headlines and minimize any step-change in company economics from these deals”. In plainer terms, it appears to be a masterclass in public relations, allowing companies to appear cooperative while the actual financial impact remains, shall we say, manageable. Craig Garthwaite, director of health care at Northwestern University’s Kellogg School of Management, was even more direct, dismissing the initiative as “a bit laughable to call this ‘the biggest thing ever’ in health policy”. He noted that Medicaid, the primary target of these cuts, already benefits from substantial discounts, often exceeding 80% in some cases, and the deals largely bypass the larger private insurance and Medicare markets.
Meanwhile, major health insurers like Cigna, CVS Health, Elevance Health, and UnitedHealth Group experienced an initial dip of about 1% following Trump’s comments, only to quickly recover. It seems even the insurance giants understand that when it comes to Trump’s policy pronouncements, the market’s initial gasp is often followed by a shrug.
Truth, Fusion, and the Future of… Social Media?
Just when the market thought it had a handle on the usual Trump-induced gyrations, a truly unexpected announcement landed with a thud: Trump Media & Technology Group (DJT), the parent company of Truth Social, declared on December 18, 2025, its intention to merge with TAE Technologies, a privately held nuclear fusion power company. Yes, you read that correctly. The company behind a social media platform that, according to a November Pew Research Center report, only 3% of Americans have ever used, is now venturing into the cutting-edge, and notoriously capital-intensive, world of fusion energy.
The all-stock transaction values the combined entity at a cool $6 billion, a significant bump from DJT‘s $4.16 billion market capitalization just prior to the news. Unsurprisingly, investors reacted with a mixture of bewilderment and enthusiasm. On Thursday, December 18, DJT shares surged by a staggering 42%, closing at $14.86, with trading volume skyrocketing to 99.5 million shares – a whopping 1265% above its three-month average. The momentum continued into Friday morning, December 19, with DJT opening at $15.32, marking a 3.10% gain from the previous day’s close. This sudden burst of investor confidence is particularly notable given that DJT‘s stock had been down almost 60% since the beginning of the year.
The merger’s sheer incongruity did not escape the notice of market observers. Dan Ives, an analyst at Wedbush, optimistically framed the deal as “a major play on creating the first public nuclear fusion company in the U.S.” and suggested that TAE would likely receive “major political support from President Trump”. Others were less sanguine. Robert Weissman, co-president of Public Citizen, offered a more cynical assessment, branding it “the marriage of a failed company and a fantasy company” and hinting at the prospect of Trump “siphon[ing] money directly from the federal government into his family’s coffers”. Rep. Don Beyer (D-VA) echoed these concerns, calling for Congressional oversight due to “significant concerns about conflicts of interest and avenues for potential corruption”. Perhaps the most succinct reaction came from Princeton University professor Jesse Jenkins, who simply called it “probably the most bonkers real headline I’ve read in forever”. Indeed, in a market where logic often takes a backseat to narrative, the Truth Social-TAE merger has set a new standard for speculative audacity.
Tariff Time: A Market Rollercoaster (Again)
No discussion of Trump’s market impact would be complete without a revisit to his favorite economic lever: tariffs. Throughout 2025, the threat, imposition, and occasional retraction of tariffs have continued to serve as a reliable source of market volatility. The latest skirmishes involved China, with Trump threatening a cooking oil embargo in October 2025 in retaliation for Beijing’s boycott of U.S. soybeans. This was followed by threats of “massive” new tariffs on Chinese imports, once again raising the specter of a full-blown trade war.
The market’s reaction to these pronouncements has been a predictable, if painful, rollercoaster. An April 2025 tariff announcement, for instance, triggered a staggering $5 trillion two-day market wipeout. The S&P 500 plunged by more than 10%, marking one of its worst two-day performances since World War II, while the tech-heavy Nasdaq Composite dropped almost 6% on both days, officially entering bear market territory, down 22% from its December peak. Similarly, in October 2025, renewed tariff threats from the U.S. and retaliatory measures from China (including export controls on rare earth elements and new port fees) led to significant declines across major indices. The S&P 500 fell approximately 1.5%, the Dow Jones Industrial Average retreated by 0.8% to 1.2%, and the Nasdaq Composite dropped between 2% and 2.5% on October 10, 2025. Technology stocks, notably Qualcomm (QCOM), bore the brunt of this sell-off.
Yet, the market’s resilience has been equally remarkable. Despite the initial shockwaves, stocks have often recovered to new highs as tariff threats were selectively paused or negotiated. This pattern suggests that while the market dislikes uncertainty, it has also learned to adapt, or perhaps simply to hope for the best, when it comes to Trump’s trade policies. However, the economic impact is not without consequence. The Federal Open Market Committee (FOMC) has attributed part of the 3.0% inflation rate recorded in September 2025 to the ongoing impact of trade policy, with Fed Chair Powell explicitly stating that “It’s really tariffs that are causing most of the inflation overshoot”. UBS strategists, while predicting “selective new tariffs” under a “Trump 2.0” administration, also warned of a “tariff shock” bear case, highlighting the persistent risk of significant market disruption.
The Show Goes On
As 2025 draws to a close, the financial markets continue to navigate the unique landscape shaped by Donald Trump’s influence. Whether through “historic” drug deals that benefit pharma stocks, a bizarre merger between a struggling social media platform and a nuclear fusion company, or the perennial threat of trade wars, Trump remains a singular force. His impact is a blend of policy, personality, and sheer unpredictability, creating a market environment where traditional analysis often takes a backseat to anticipating the next headline. For investors, it’s less about fundamental economics and more about a high-stakes game of political poker, where the dealer frequently changes the rules mid-hand. And for those watching from the sidelines, it’s an endlessly entertaining, if occasionally terrifying, show.
DISCLAIMER: We read Trump’s posts so you don’t have to. This is comedy meets market data, not financial advice. Not political advice either – we just like charts and chaos.
Elana Harper is a seasoned financial editor and market analyst with over a decade of experience covering global equities, economic trends, and corporate earnings. Known for her sharp insights, Elana specializes in making complex financial topics accessible to a broad audience. She now serves as the Senior Financial Editor at Stock Market Watch, where she oversees daily market coverage and political commentary.